INLB (INLB) Stock Price & Analysis
INLB (INLB) rose 0.00% to USD 0 as of June 10, 2026 at 03:11 UTC, according to Nexqual real-time market data.
INLB last closed at USD 0; the session ranged USD 0–0 on volume of 20,000 shares. Market capitalization is $10,236, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 03:11 UTC.
Key Statistics (as of June 10, 2026 at 03:11 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 20,000 shares |
| Market Cap | $10,236 |
| Exchange | PNK |
Technical Analysis (INLB)
Nexqual's technical model rates INLB "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:11 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (INLB)
Wall Street analysts rate INLB "None", per Nexqual as of June 10, 2026 at 03:11 UTC.
| Consensus Rating | None |
|---|
Earnings (INLB)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2022-12-31 | USD -0.03 vs est -0.05 ▲ beat |
| 2022-09-30 | USD -0.07 vs est -0.04 ▼ miss |
| 2022-06-30 | USD -0.06 vs est -0.03 ▼ miss |
| 2022-03-31 | USD -0.04 vs est -0.03 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:11 UTC.
Financials & Fundamentals (INLB)
| Total Revenue | $19.69M |
|---|---|
| Revenue Growth (YoY) | +1.80% |
| Gross Margin | +49.79% |
| Operating Margin | -55.70% |
| Profit Margin | -157.61% |
| ROE | -47.36% |
| Debt / Equity | 65.15 |
| Current Ratio | 0.06 |
| Total Cash | $183,429 |
| Total Debt | $34.30M |
| Free Cash Flow | $9.99M |
Source: Nexqual, June 10, 2026 at 03:11 UTC.
Financial Health Score (INLB)
Nexqual rates INLB's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:11 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $183K cash vs $34M debt |
| Cash Flow | Strong — FCF $10M, 46% margin |
| Efficiency | Critical — ROE -47%, ROA -5.4% |
Ownership (INLB)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 102.36M |
| Float | 100.76M |
Source: Nexqual, June 10, 2026 at 03:11 UTC.
Leadership (INLB)
INLB is led by Jeffrey I. Rassas (age 62), Strategic Advisor & Director, per Nexqual as of June 10, 2026 at 03:11 UTC.
| Strategic Advisor & Director | Jeffrey I. Rassas (age 62) |
|---|---|
| Senior Vice President of Communications | Jayne Levy |
| Vice President of Marketing | Kyle Jennings |
| Senior Vice President of Corporate Development | Mark Busch |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACBM | ACRO BIOMEDICAL CO LTD | USD 0.03 | ▲ 0% |
| NMTRQ | 9 Meters Biopharma, Inc. | USD 0 | ▲ 0% |
| STMH | STEM HOLDINGS INC | USD 0 | ▲ 0% |
| ILAL | International Land Alliance Inc | USD 4.07 | ▼ 21.73% |
| FFNTF | 4Front Ventures Corp. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:11 UTC. This page is informational and not investment advice.